Adjuvant chemotherapy for breast cancer and cognitive impairment.
South Med J
; 102(9): 929-34, 2009 Sep.
Article
in En
| MEDLINE
| ID: mdl-19668023
ABSTRACT
Complaints of loss of memory and lack of concentration have been reported by long-term survivors of breast cancer. This mild cognitive impairment (MCI), also called "chemobrain" or "chemofog," has been the subject of a number of studies in the last few years. This cognitive impairment, although usually mild, must be studied to define possible risk factors for its development, and for future research into a preventive or therapeutic treatment approach. Long-term survivors of breast cancer must be followed to detect possible treatment sequelae as soon as possible. Since the number of these long-term survivors has increased in the last years, in part because of more active adjuvant treatments, our knowledge about the long-term side effects of these therapies has also grown.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Chemotherapy, Adjuvant
/
Cognition Disorders
Type of study:
Diagnostic_studies
/
Etiology_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
Language:
En
Journal:
South Med J
Year:
2009
Type:
Article
Affiliation country:
Spain